IGC Pharma’s AI Identifies New GLP-1 Agonist Potential for Metabolic and Alzheimer’s Treatments

IGC Pharma has used sophisticated Artificial Intelligence (AI) modelling to identify their patented compound, IGC-1A, as a putative GLP-1 agonist. This finding demonstrates the adaptability of IGC Pharma's therapeutic platforms and the business's prospective for growth into metabolic diseases and weight reduction. The neuroprotective properties of GLP-1, a hormone well-known for its dual functions in controlling blood sugar levels and encouraging weight reduction, are also being investigated. By treating inflammation and oxidative stress, this has the potential to revolutionise Alzheimer's disease therapies and provide a multimodal approach to better patient outcomes.

The CEO of IGC Pharma, Ram Mukunda, said that the AI-driven strategy has shown a strong chance for IGC-1A and IGC-1C to be potential GLP-1 agonists, bolstering their therapy portfolio for Alzheimer's and putting them in a position to possibly join the quickly expanding weight loss market. Based on a comparison between IGC-1A and IGC-1C and well-known medications such as metformin, oxipepticde, retatrutide, and tiripepatide, IGC Pharma's AI model suggests that they may prove to be useful treatments for metabolic diseases.

IGC Pharma sees significant development potential in creating novel medicines for metabolic and neurological disorders as more validation through clinical trials advances. IGC-1A may be a GLP-1 agonist, GIP agonist, and CB1r inverse agonist, according to research on the protein. These findings open up new treatment options for neurological, metabolic, and weight-related conditions.